Cariprazine Depot Phase I/II Study Recruits First Patient
Mapi Pharma has enrolled the first patient in a multinational Phase I/II study of its once-monthly injectable cariprazine for...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Mapi Pharma has enrolled the first patient in a multinational Phase I/II study of its once-monthly injectable cariprazine for...
In a reanalysis of a prior trial in 56 male veterans with treatment‑resistant PTSD, participants who achieved at least...
The UK’s MHRA has granted Clinical Trial Authorisation for NVG-222, clearing a first-in-human, Phase I/II adaptive basket study in...
Phase 1 data for TNX-4800 (mAb 2217LS) showed safety and tolerability with a linear pharmacokinetic:pharmacodynamic: efficacy relationship, supporting dose...
A multicenter pediatric trial of Vivos Therapeutics’ DNA (Daytime-Nighttime Appliance) reported that 77% of participants achieved at least a...
Ex vivo human IPF lung slices exposed to LTI-03 showed reductions across TGFβ, VEGF, PDGF, and FGF signaling, along...
No efficacy or safety data were released. Kalaris has begun enrolling a Phase 1b/2 multiple ascending dose study of...
In a retrospective EHR cohort spanning 2015–2024, Stanford Health Care identified 181 patients with epilepsy treated with clobazam oral...
Kalaris has opened enrollment for a Phase 1b/2 multiple-ascending-dose study of TH103 in neovascular AMD, targeting up to 80...
Spyre Therapeutics has dosed the first patient in SKYWAY, a randomized, placebo-controlled Phase 2 basket trial of SPY072, an...